EUVIMEDEUVIMED entdecken
Crossref

Periconceptional Hormonal Contraception Use and Autism Spectrum Disorder in the Study to Explore Early Development

Michelle T Delahanty iD, Stephanie Engel, Dani Fallin, Tanya Garcia, Christine Ladd-Acosta iD, Anne Steiner, Mollie Wood iD, Julie L Daniels

Paediatric and Perinatal Epidemiology · 2025

DOI: 10.1111/ppe.70049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Paediatric and Perinatal Epidemiology, 2025. Verfasst von Michelle T Delahanty und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Prenatal Exposure Delayed Effects, Hormonal Contraception. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Institute of Child Health and Human Development, CDC HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prior studies report associations between periconceptional exposure to natural and synthetic oestrogen and progesterone and autism spectrum disorder (ASD). Hormonal contraception contains synthetic forms of one or both hormones. Although hormonal contraception is highly effective when consistently used, unintended pregnancy can occur with irregular use. Given the popularity of hormonal contraception, foetal exposure in utero is possible, yet the potential consequences are unknown.

Objectives

We investigated the association between periconceptional hormonal contraception use and the development of ASD in offspring.

Methods

We analysed data from the Study to Explore Early Development (SEED), a population‐based case–control study conducted in select US states, from 2007 to 2020. Children with and without ASD were identified from clinical/education sources and vital records, respectively, and enrolled at ages 2.5–5 years. We confirmed the ASD case status by in‐person developmental assessment. We assessed hormonal contraception via a structured interview. We assessed the associations between ASD and hormonal contraception exposure separately for contraception discontinued in the 3 months prior to pregnancy and contraception continued during pregnancy using logistic models to estimate odds ratios (OR) adjusted for biological mother age, education, parity, pre‐pregnancy body mass index (BMI), and presence of gynaecologic conditions and 95% confidence intervals (CI).

Results

Of 5210 participants, 9.9% reported discontinuing hormonal contraception use before pregnancy and 2.3% reported continuing use during pregnancy. A suggestive association was found between ASD and hormonal contraception use during pregnancy (aOR 1.38,95% CI 0.93, 2.05). There was no association with use prior to pregnancy (aOR 1.02, 95% CI 0.84, 1.25).

Conclusions

Discontinuation of hormonal contraception prior to conception was not associated with ASD. The prevalence of hormonal contraception use during pregnancy was low. Results were imprecise and may be impacted by recall bias and unmeasured confounding by indication and health behaviours related to planning pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autism Spectrum DisorderPrenatal Exposure Delayed EffectsHormonal ContraceptionHumansFemalePregnancyChild, PreschoolCase-Control StudiesUnited StatesAdultMale

Autor:innen und Institutionen

  • Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • School of Public Health, Emory University Rollins, Atlanta, Georgia, USA.
  • School of Public Health, Johns Hopkins Bloomberg, Baltimore, Maryland, USA.
  • School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID-Profile: Michelle T Delahanty, Christine Ladd-Acosta, Mollie Wood

Förderung

  • National Institute of Child Health and Human Development
  • CDC HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Centers for Disease Control and Prevention

Zitieren

APA

Delahanty, M. T., Engel, S., Fallin, D., Garcia, T., Ladd-Acosta, C., Steiner, A., Wood, M., & Daniels, J. L. (2025). Periconceptional Hormonal Contraception Use and Autism Spectrum Disorder in the Study to Explore Early Development. Paediatric and Perinatal Epidemiology. https://doi.org/10.1111/ppe.70049

Vancouver

Delahanty MT, Engel S, Fallin D, Garcia T, Ladd-Acosta C, Steiner A, et al. Periconceptional Hormonal Contraception Use and Autism Spectrum Disorder in the Study to Explore Early Development. Paediatric and Perinatal Epidemiology. 2025. doi:10.1111/ppe.70049

BibTeX
@article{Delahanty2025,
  author = {Delahanty, Michelle T and Engel, Stephanie and Fallin, Dani and Garcia, Tanya and Ladd-Acosta, Christine and Steiner, Anne and Wood, Mollie and Daniels, Julie L},
  title = {Periconceptional Hormonal Contraception Use and Autism Spectrum Disorder in the Study to Explore Early Development},
  journal = {Paediatric and Perinatal Epidemiology},
  year = {2025},
  doi = {10.1111/ppe.70049}
}
Kostenlos starten →